Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1381-1400 of 1,738 trials

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Hepatocellular Carcinoma: NMS-01940153E and Atezolizumab Study

We are studying a new treatment combination for adults with unresectable hepatocellular carcinoma who have been treated with other anti-cancer medicines. The goal is to see how well this combination works and its safety compared to existing options.

Unresectable Hepatocellular CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesHepatologyOncology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Cutaneous Lupus Erythematosus: IMVT-1402 Study

We are evaluating a new treatment for people with active cutaneous lupus erythematosus to see if it improves skin symptoms compared to a placebo. This study aims to assess its safety and effectiveness.

Skin Lupus1-2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementDermatologyRheumatology

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Diffuse Large B-Cell Lymphoma: Glofitamab with Gemcitabine and Oxaliplatin

We are studying a new treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma. The focus is on understanding the safety and frequency of cytokine release syndrome with this therapy.

Refractory Diffuse Large B-Cell Lymphoma6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Visugromab Treatment

We are studying whether visugromab, combined with standard chemotherapy, can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. The trial also looks at safety and quality of life during treatment.

Metastatic Non-Squamous Non-Small Cell Lung CancerEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Non-Squamous Non-Small Cell Lung Cancer: Visugromab and Nivolumab Study

We are investigating whether a new treatment combining visugromab and nivolumab with or without docetaxel can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. This study will help us understand its effectiveness and safety compared to standard treatments.

Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Solid Tumors: MK-3120 Treatment Study

We are testing a new treatment called MK-3120 for people with advanced solid tumors to see how safe it is and if it can help reduce tumor size.

Advanced Solid Tumor Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

CAR-T Cell Therapy for Autoimmune Diseases

We are studying a new CAR-T cell treatment for patients with active autoimmune diseases like lupus, systemic sclerosis, and inflammatory myopathy. The trial aims to assess safety and how well this therapy works in reducing disease symptoms.

Systemic SclerosisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathy6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyNeurologyRheumatology

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics